Mirati Therapeutics Presents Positive Clinical Data with Investigational Adagrasib as Monotherapy and in Combination with Cetuximab in Patients with KRAS G12C-Mutated Colorectal Cancer - SC Read more about Mirati Therapeutics Presents Positive Clinical Data with Investigational Adagrasib as Monotherapy and in Combination with Cetuximab in Patients with KRAS G12C-Mutated Colorectal Cancer - SC
Novocure Announces Clinical Trial Collaboration with Roche to Evaluate Tumor Treating Fields as Part of a Novel Combination for the First-line Treatment of Metastatic Pancreatic Cancer - SC Read more about Novocure Announces Clinical Trial Collaboration with Roche to Evaluate Tumor Treating Fields as Part of a Novel Combination for the First-line Treatment of Metastatic Pancreatic Cancer - SC
Mirati Therapeutics Clinical Research at ESMO Congress 2021 to Highlight Progress with Investigational Adagrasib and Sitravatinib in Patients with Lung and Colorectal Cancers - SC Read more about Mirati Therapeutics Clinical Research at ESMO Congress 2021 to Highlight Progress with Investigational Adagrasib and Sitravatinib in Patients with Lung and Colorectal Cancers - SC
Novocure Presents Final Safety and Efficacy Results from its Phase 2 Pilot HEPANOVA Trial in Liver Cancer - SC Read more about Novocure Presents Final Safety and Efficacy Results from its Phase 2 Pilot HEPANOVA Trial in Liver Cancer - SC
再鼎医药合作伙伴Mirati Therapeutics 宣布Adagrasib 获美国FDA授予突破性疗法认定，用于治疗携带 KRAS G12C 突变的晚期非小细胞肺癌 Read more about 再鼎医药合作伙伴Mirati Therapeutics 宣布Adagrasib 获美国FDA授予突破性疗法认定，用于治疗携带 KRAS G12C 突变的晚期非小细胞肺癌
argenx announces publication of Phase 3 ADAPT trial results of efgartigimod for the treatment of generalized myasthenia gravis in The Lancet Neurology - SC Read more about argenx announces publication of Phase 3 ADAPT trial results of efgartigimod for the treatment of generalized myasthenia gravis in The Lancet Neurology - SC
Turning Point Therapeutics Granted FDA Orphan Drug Designation for TPX-0022 in Gastric Cancer - SC Read more about Turning Point Therapeutics Granted FDA Orphan Drug Designation for TPX-0022 in Gastric Cancer - SC
Cullinan Oncology Announces Phase 1/2a Interim Data For Cullinan Pearl’s CLN-081 in NSCLC EGFR Exon 20 Patients - SC Read more about Cullinan Oncology Announces Phase 1/2a Interim Data For Cullinan Pearl’s CLN-081 in NSCLC EGFR Exon 20 Patients - SC
Paratek Pharmaceuticals Announces FDA Approval of NUZYRA® (omadacycline) Oral Only Dosing Regimen for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) - SC Read more about Paratek Pharmaceuticals Announces FDA Approval of NUZYRA® (omadacycline) Oral Only Dosing Regimen for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) - SC
Novocure Announces FDA Approval of IDE Supplement for Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer - SC Read more about Novocure Announces FDA Approval of IDE Supplement for Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer - SC